Page 23 - Priority Review News Today

 Age-Related Molecular Degeneration IndustryAge-related molecular degeneration industry size has a projected US$ 11.28 million market valuation worldwide in 2023, with a compound annual growth rate (CAGR) of 7%. By 2033, the healthcare technology industry is anticipated to reach US$ 22.19 million due to technologica...

The FDA has accepted for Priority Review the BLA for omalizumab for the reduction of allergic reactions in patients with food allergies.

MAPS Public Benefit Corporation is seeking approval of its MDMA (midomafetamine capsules)-assisted therapy for posttraumatic stress disorder.

– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III...

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it...

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...

The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.

The FDA has accepted for Priority Review the BLA for V116, an investigational 21-valent pneumococcal conjugate vaccine for adults.

In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.

The U.S. Food and Drug Administration (FDA) has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, which could be a lifesaver for people dealing with the disease who are